Search
Urelumab
go.drugbank.com/drugs/DB12077InvestigationalThe antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with
Totrombopag
go.drugbank.com/drugs/DB05930InvestigationalThis drug is developed by GlaxoSmithKline and used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled bleeding
1-Deoxy-D-xylulose 5-phosphate
go.drugbank.com/drugs/DB02496ExperimentalThese are carbohydrate derivatives containing a pentose substituted by one or more phosphate groups.
Osanetant
go.drugbank.com/drugs/DB04872InvestigationalDeveloped by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System
LV-SMENP Vaccine
go.drugbank.com/drugs/DB15804ExperimentalLV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which
Sodium copper chlorophyllin
go.drugbank.com/drugs/DB16522InvestigationalSCC of the commercial-grade is prepared from a reaction between a crude chlorophyll extract and methanolic sodium hydroxide, followed by replacement of the central magnesium atom with a heavy metal[A227718
UCB-1184197
go.drugbank.com/drugs/DB05092InvestigationalCDP323 was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.
Asimadoline
go.drugbank.com/drugs/DB05104InvestigationalAsimadoline is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis.
Cintredekin besudotox
go.drugbank.com/drugs/DB05305InvestigationalCintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual
Regramostim
go.drugbank.com/drugs/DB05386InvestigationalRegramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages.